Yale, Mayo and FDA experts aim to rethink heart failure trials with Apple WatchA group of scientists from Yale University and the Mayo Clinic are to use an Apple Watch app Share XYale, Mayo and FDA experts aim to rethink heart failure trials with Apple Watchhttps://pharmaphorum.com/news/yale-mayo-and-fda-experts-aim-to-rethink-heart-failure-trials-with-apple-watch/
Genentech extends small-molecule R&D with three platform dealsRoche’s Genentech unit signed a trio of deals this week to add new drug discovery platforms to its Share XGenentech extends small-molecule R&D with three platform dealshttps://pharmaphorum.com/news/genentech-extends-small-molecule-rd-with-three-platform-deals/
Boehringer announces IPF deal with Korea’s Bridge TherapeuticsBoehringer Ingelheim and South Korean biotech Bridge Biotherapeutics have announced a deal to develop the latter’s drug for Share XBoehringer announces IPF deal with Korea’s Bridge Therapeuticshttps://pharmaphorum.com/news/boehringer-announces-ipf-deal-with-koreas-bridge-therapeutics/
Takeda looking to divest portfolio of older drugs in EuropeTakeda is trying to sell a portfolio of older drugs in western Europe as it seeks to cut Share XTakeda looking to divest portfolio of older drugs in Europehttps://pharmaphorum.com/news/takeda-looking-to-divest-portfolio-of-older-drugs-in-europe/
Denmark’s Genmab raises a bumper $500m-plus in Nasdaq IPOGenmab has shattered recent records with its Nasdaq listing, raising $506 million to help it advance multiple antibody Share XDenmark’s Genmab raises a bumper $500m-plus in Nasdaq IPOhttps://pharmaphorum.com/news/denmarks-genmab-raises-a-bumper-500m-plus-in-nasdaq-ipo/
Huami set to launch ECG watches outside ChinaHuami is to make its new crop of electrocardiogram smartwatches available to international markets, according to a press Share XHuami set to launch ECG watches outside Chinahttps://pharmaphorum.com/news/huami-set-to-launch-ecg-watches-outside-china/
FDA clears Bayer’s Gadavist as first contrast agent for cardiac MRIBayer’s Gadavist has become the first imaging agent approved in the US to detect blockages in the hearts Share XFDA clears Bayer’s Gadavist as first contrast agent for cardiac MRIhttps://pharmaphorum.com/news/fda-clears-bayers-gadavist-as-first-contrast-agent-for-cardiac-mri/
Gilead’s R&D chief to step down as new CEO O’Day rings the changesGilead’s chief scientific officer, John McHutchison is to leave the company at the beginning of next month during Share XGilead’s R&D chief to step down as new CEO O’Day rings the changeshttps://pharmaphorum.com/news/gileads-rd-chief-to-step-down-as-new-ceo-oday-rings-the-changes/
Novartis ups 2019 guidance after strong Q2Novartis has revised its guidance for 2019 upwards after a strong set of Q2 figures, with its psoriasis Share XNovartis ups 2019 guidance after strong Q2https://pharmaphorum.com/news/novartis-ups-2019-guidance-after-strong-q2/
